BL-122

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C22H19N3O5
Molecular Weight	405.4034
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1CC(=O)N[C@H](CC2=C(NC3=CC=CC=C23)C(=O)C4=CC=C5OCOC5=C4)C1=O

InChI

InChIKey=SXWTYPIIBMLMNG-MRXNPFEDSA-N

InChI=1S/C22H19N3O5/c1-25-10-19(26)23-16(22(25)28)9-14-13-4-2-3-5-15(13)24-20(14)21(27)12-6-7-17-18(8-12)30-11-29-17/h2-8,16,24H,9-11H2,1H3,(H,23,26)/t16-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C22H19N3O5
Molecular Weight	405.4034
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 18:49:46 GMT 2023` Edited by `admin` on `Sat Dec 16 18:49:46 GMT 2023`
Record UNII	C6EK6NL6LL
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BL-122

Code

English

2,5-PIPERAZINEDIONE, 3-((2-(1,3-BENZODIOXOL-5-YLCARBONYL)-1H-INDOL-3-YL)METHYL)-1-METHYL-, (3R)-

Systematic Name

English

BL122

Code

English

(3R)-3-((2-(1,3-BENZODIOXOL-5-YLCARBONYL)-1H-INDOL-3-YL)METHYL)-1-METHYL-2,5-PIPERAZINEDIONE

Systematic Name

English

(R)-3-((2-(BENZO(D)(1,3)DIOXOLE-5-CARBONYL)-1H-INDOL-3-YL)METHYL)-1-METHYLPIPERAZINE-2,5-DIONE

Systematic Name

English

Code System Code Type Description

EPA CompTox

DTXSID00669818

Created by admin on Sat Dec 16 18:49:46 GMT 2023 , Edited by admin on Sat Dec 16 18:49:46 GMT 2023

PRIMARY

CAS

1220393-12-3

Created by admin on Sat Dec 16 18:49:46 GMT 2023 , Edited by admin on Sat Dec 16 18:49:46 GMT 2023

PRIMARY

PUBCHEM

45109887

Created by admin on Sat Dec 16 18:49:46 GMT 2023 , Edited by admin on Sat Dec 16 18:49:46 GMT 2023

PRIMARY

FDA UNII

C6EK6NL6LL

Created by admin on Sat Dec 16 18:49:46 GMT 2023 , Edited by admin on Sat Dec 16 18:49:46 GMT 2023

PRIMARY

Related Record Type Details


					C6EK6NL6LL

BL-122

ACTIVE MOIETY

Comments:

Originator: Biolab Sanus Farmaceutica; Class: Anti-infective, Antifungal; Mechanism of Action: Undefined mechanism; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phase: Phase I for Mycoses; Most Recent Event: 01 Jan 2014 Phase-I clinical trials in Mycoses in Brazil (unspecified route)